Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost
link : Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost

Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost

Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost
By Josh Bloom — October 5, 2017

I have also written about the benefit of second- and third-generation drugs, which are dismissed as "me-too" drugs by know-nothing critics of the industry, such as Sidney Wolfe and Marcia Angell. Ignorant critics would have you believe that the fourth approved drug in a class is nothing more than a non-innovative cash cow for drug companies. They could hardly be more wrong.

It is now clear that patients benefit greatly when there are multiple choices of drugs for a particular ailment; not just medically, but also economically. There can be no better example of this than AbbVie's Mavyret, the newest weapon in the already-impressive arsenal against hepatitis C—a pernicious virus that has infected 3 million people in the US and 170 million worldwide.

Read More http://ift.tt/2y1uJEZ

Thus articles Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost

that is all articles Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Hepatitis C "Me-Too" Drugs: Innovation And Lower Cost the link address https://newsaninpiration.blogspot.com/2017/10/hepatitis-c-me-too-drugs-innovation-and.html

Tweet

Subscribe to receive free email updates: